Epsilogen
Developer of immunoglobulin E (IgE) antibodies to treat cancer.
7
Funding Rounds
$117.3m
Money raised
Overview
Developer of immunoglobulin E (IgE) antibodies to treat cancer.
- Website:
- Business model: B2B
- Headquarters: London
- Social accounts: linkedin
Funding
Funding series
Funding Series Analysis
The company Epsilogen has raised a total of $117.3m in funding over 7 rounds.
Key Insights:
- Epsilogen Series B Round, September 2024: $16.5m
- Epsilogen Series B round, March 2022: $41.2m
- Epsilogen February 2022 Funding Round: $42m
- Epsilogen November 2018 Series A Funding Round: $6.3m
- Epsilogen November 2018 Series A Funding Round: $6.3m
- Epsilogen June 2017 Series A Funding Round: $2.5m
- Epsilogen June 2017 Series A Funding Round: $2.5m
Epsilogen Series B Round, September 2024
$16.5m
Epsilogen Series B round, March 2022
$41.2m
Epsilogen February 2022 Funding Round
$42m
Epsilogen November 2018 Series A Funding Round
$6.3m
Epsilogen November 2018 Series A Funding Round
$6.3m
Epsilogen June 2017 Series A Funding Round
$2.5m
Epsilogen June 2017 Series A Funding Round
$2.5m
Industries
Epsilogen is active in the following industries: